Accelerate your research with our Artificial Intelligence Platforms

As Microbiome is a part of a bigger system we integrate sequencing data analysis with other measured parameters which leads to multidimensional findings. Such complex datasets usually leave standard analytical technologies clueless, but not Ardigen’s Microbiome Translational Platform powered by cutting-edge AI algorithms.

Deep learning-based Function discovery enables translation of identified microbial signatures into biologically meaningful information.  Our technology has proven its value aiding multiple companies with improvement of their clinical trials, design of biomarkers or start of the development of novel therapeutics.

Is your microbiome data a mystery? At Ardigen we:

• Easily identify bacterial signatures that contribute the most to the given host phenotype
• obtain results generalizing for broad population
• Integrate the metagenomic information with other -omic data and clinical parameters
• Derive conclusions and predictions from time point data
• Run your analysis while maintaining a high level of result credibility with the aid of thorough validation procedures

Decoding microbiome with AI. With us you can:

• Squeeze more information from your metagenomic data with deep learning
• Access more functional meaning of metagenome than with standard bioinformatic pipelines
• Apply cutting-edge AI to understand bacterial functions
• Use AI-based metagenomic functional traits to predict patient phenotypes
• Discover novel microbial biomarkers based on comprehensive metagenome analysis
• Validate your biomarkers in silico

Custom offer

• Do you need help with unique microbiome-related project? 

We are always excited to work in one of a kind projects that stimulates our development!

We have created an artificial intelligence platform dedicated to be a part of the cancer vaccine development process. 

ArdImmune Vax AI Platform uses sequencing data to generate and prioritize antigen targets of cancer vaccines and T-cell therapies. The platform comprises of bioinformatics and machine learning set of algorithms that generate putative antigens, assess patient’s MHC, antigen(peptide)-MHC binding affinity, likelihood of peptide presentation by the MHC molecules on the cell surface, likelihood of pMHC attracting T-cells to generate functional responses described as immunogenicity.

Following the unique opportunity for curing patients provided by the development of cell therapies, Ardigen has set on a path to advance the field with the application of its artificial intelligence platform. 

Ardigen’s TCRact AI Platform uses target peptide and MHC sequences, as well as TCR sequences, to assess target fitness for the use in TCR therapy. The scope of the platform entails also the following analyses: pMHC:TCR complex binding affinity, stability, suggestions of TCR sequence improvements, assessment of potential off-target activity of TCR, generation of novel TCR sequences matching the desired specificity and safety profile.